爱尔眼科：公司陆续推出ICL V5、全飞秒Pro、全飞秒4.0、全光塑等升级术式

Core Viewpoint - The company maintains international synchronization and domestic leadership in refractive technology, advocating the principle that "the best is what suits" while offering personalized and precise medical services [1] Group 1: Technological Advancements - The company has introduced various upgraded surgical techniques in the past two years, including ICLV5, all-laser femtosecond Pro, all-laser femtosecond 4.0, and all-light plastic surgery, to meet diverse patient needs [1] - The all-laser femtosecond Pro technique, introduced in mid-2025, achieved a cumulative surgical volume of over 10,000 cases by January 2026, accounting for approximately 25% of the total in the domestic market [1] - The company is a significant promoter and contributor to the all-light plastic surgery technique, enhancing patient experience with shorter surgery times and better visual quality [1] Group 2: Competitive Advantages - The company leverages its network, expert, brand, and popular science advantages to accelerate the promotion of new technologies, reinforcing its first-mover advantage in the domestic ophthalmology market [1] - The company plays a multiplicative role for upstream manufacturers, which is challenging to achieve in fragmented markets [1]